Objectives: Literature regarding appropriate use of inhaled nitric oxide for pediatric acute respiratory distress syndrome is sparse. This study aims to determine if positive response to inhaled nitric oxide is associated with decreased mortality and duration of mechanical ventilation in pediatric acute respiratory distress syndrome. Design: Retrospective cohort study. Setting: Large pediatric academic medical center. Patients or Subjects: One hundred sixty-one children with pediatric acute respiratory distress syndrome and inhaled nitric oxide exposure for greater than or equal to 1 hour within 3 days of pediatric acute respiratory distress syndrome onset. Interventions: Patients with greater than or equal to 20% improvement in oxygenation index or oxygen saturation index by 6 hours after inhaled nitric oxide initiation were classified as "responders. " Measurements and Main Results: Oxygenation index, oxygen saturation index, and ventilator settings were evaluated prior to inhaled nitric oxide initiation and 1, 6, 12, and 24 hours following inhaled nitric oxide initiation. Primary outcomes were mortality and duration of mechanical ventilation. Baseline characteristics, including severity of illness, were similar between responders and nonresponders. Univariate analysis showed no difference in mortality between responders and nonresponders (21% vs 21%; p = 0.999). Ventilator days were significantly lower in responders (10 vs 16; p < 0.001). Competing risk regression (competing risk of death) confirmed association between inhaled nitric oxide response and successful extubation (subdistribution hazard ratio = 2.11; 95% CI, 1.41-3.17; p < 0.001). Response to inhaled nitric oxide was associated with decreased utilization of high-frequency oscillatory ventilation and extracorporeal membrane oxygenation and lower hospital charges (difference in medians of $424,000). Conclusions: Positive response to inhaled nitric oxide was associated with fewer ventilator days, without change in mortality, potentially via reduced use of high-frequency oscillatory ventilation and extracorporeal membrane oxygenation. Future studies of inhaled nitric oxide for pediatric acute respiratory distress syndrome should stratify based on oxygenation response, given the association with favorable outcomes. (Pediatr Crit Care Med 2017; 18:1019-1026 Key Words: acute respiratory distress syndrome; acute respiratory failure; hypoxia; inhaled nitric oxide; pediatric acute respiratory distress syndrome P ediatric acute respiratory distress syndrome (PARDS) is a common illness requiring admission to the PICU and a significant contributor to PICU mortality (1-3). Though always defined by hypoxemia and respiratory distress, the etiology, patient population affected, and natural history
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of the illness can be quite heterogeneous (4) . Due to this heterogeneity and lack of data to guide treatment, management of PARDS varies widely across institutions and between providers. An exemplar of this is the use of inhaled nitric oxide (iNO), a pulmonary vasodilator and modulator of endothelial function, to treat refractory PARDS. Despite multiple adult and pediatric studies showing no improvement in mortality with iNO therapy (5) (6) (7) (8) (9) (10) , this expensive therapy is used in up to 13% of PARDS cases (4) in an effort to improve hypoxemia. Additionally, a meta-analysis (10) of the available data only included three pediatric patients, and a recent pediatric propensitymatched study (11) was unable to match based on patient illness measures, leading to exclusion of many iNO-exposed patients from analysis. Therefore, it is difficult to extrapolate conclusions from either study to clinical practice. Furthermore, all studies have analyzed patients as a homogenous cohort despite the known heterogeneity of disease severity and course. There is also evidence of variability at the cellular level, as exemplified by angiopoietin 2, a biomarker of endothelial dysfunction whose levels are variable across patients and highest in PARDS nonsurvivors (12) . In addition to physiologic and pathophysiologic heterogeneity in PARDS, therapeutic response to iNO varies across patients (1, (13) (14) (15) (16) (17) . Given this heterogeneity, it is plausible that some patient populations may benefit from iNO therapy, whereas others may not (13) . An approach for determining which patients may benefit is to stratify patients by response to iNO, rather than simply exposure to iNO. This retrospective observational cohort study aimed to determine whether patients with PARDS who respond to iNO have decreased mortality and duration of mechanical ventilation, relative to nonresponders. We hypothesized that patients who respond to iNO would have lower mortality and duration of mechanical ventilation. Additionally, given the variability of the endothelial biomarker angiopoietin 2 in PARDS and the putative effects of iNO on pulmonary vasculature, we sought to determine whether angiopoietin 2 levels differed between iNO responders and nonresponders, as an exploratory aim.
MATERIALS AND METHODS

Study Design, Patient Selection, and Data Collection
This retrospective study was approved by the Children's Hospital of Philadelphia's (CHOP) Institutional Review Board, and the requirement for informed consent waived. The PARDS cohort evaluated in this study has been previously described in detail (18) . The cohort consists of prospectively enrolled intubated children 1 month to 17 years old admitted to the CHOP PICU between July 1, 2011, and June 30, 2016, who met American-European Consensus Conference (AECC) criteria for acute lung injury (19) . The AECC definition was used because the study was initiated prior to the 2012 Berlin definition. However, as our institution does not use positive end-expiratory pressure less than 5 cm H 2 O, all patients met Berlin criteria for of ARDS (20) . Similarly, as the study was initiated prior to the 2015 Pediatric Acute Lung Injury Consensus Conference (PALICC), we did not use the PALICC definition of PARDS; however, all patients met PALICC criteria (21) .
Patients were included if exposed to iNO of any dose for at least 1 hour, within 3 days of PARDS onset, as the focus of this study was early PARDS. Absent a standard protocol in the CHOP PICU, iNO initiation is left to the discretion of the attending physician. In this cohort, iNO was universally initiated and maintained at 20 ppm for 24 hours during which oxygenation data were collected. Duration of iNO therapy and weaning in both responders and nonresponders were also left to the discretion of the treating physician. Our institution does not employ a standard practice for iNO initiation, duration, or weaning strategy or for weaning of mechanical ventilation. However, iNO and mechanical ventilation are weaned independently of each other-that is, patients do not remain intubated solely to allow iNO weaning and are frequently extubated to iNO delivery via noninvasive means once invasive mechanical ventilation is deemed no longer necessary by the attending physician.
Demographic information and clinical data were collected prospectively and compiled into a database, including PARDS etiology, comorbidities, ventilator settings, use of ancillary therapies (advanced ventilator modes), extracorporeal membrane oxygenation (ECMO), iNO duration, mortality, and duration of mechanical ventilation. The severity of illness score used was the Pediatric Risk of Mortality (PRISM) III at 12 hours. Charts were retrospectively reviewed for echocardiographic evidence of pulmonary hypertension (pHTN), defined by stated diagnosis in written report by designated pediatric cardiologist or estimated right ventricular pressure greater than half systemic mean arterial pressure. Plasma brain natriuretic peptide (BNP) levels were also recorded. Hospital charges were extracted from the CHOP billing database. Oxygenation index (OI), oxygenation saturation index (OSI), and mean airway pressure (mP aw ) were abstracted retrospectively for the following timepoints: prior to iNO initiation and at 1, 6, 12, and 24 hours following iNO initiation.
A subset of patients (n = 44) were prospectively enrolled in an ongoing cohort study of plasma angiopoietin 2 levels in PARDS (12) . Blood was collected within 24 hours of PARDS onset in citrated tubes (Becton, Dickinson and Company, Franklin Lakes, NJ), centrifuged within 30 minutes of collection (2,000 g, 20 min, 20°C) to generate platelet-poor plasma, and stored at -80°C. Angiopoietin 2 was measured in duplicate using an enzyme-linked immunosorbent assay (R & D Systems, Minneapolis, MN). Interassay coefficient of variation was 5.3%.
Definitions
The primary metric of oxygenation used was OI (mP aw × Fio 2 × 100/Pao 2 ). A positive response to iNO was defined as 20% improvement in OI by 6 hours after iNO initiation. For patients in whom OI was not computable at initiation or at 6 hours-typically due to lack of an arterial line-OSI (mP aw × Fio 2 × 100/arterial oxygen saturation [Spo 2 ]) (22) was used, ensuring that only Spo 2 values between 80% and 97% were used (23).
The designation "immunocompromised" required presence of an immunocompromising diagnosis (oncologic, immunologic, rheumatologic, or transplant) and active immunosuppressive chemotherapy or a congenital immunodeficiency (24) .
The primary outcomes were PICU mortality and duration of mechanical ventilation. All mention of "mechanical ventilation" in this study implies invasive ventilation, and noninvasive support was not counted toward total ventilator days. "Day 1" was initiation of invasive ventilation. Liberation from invasive ventilation for greater than 24 hours defined duration of mechanical ventilation. Patients requiring reinitiation of invasive ventilation after 24 hours of extubation had the extra days counted toward total ventilator days.
Data Analysis
Data are expressed as percentages or median (interquartile range). Categorical variables were analyzed by Fisher exact test. Continuous variables were compared using Wilcoxon ranksum test. Changes in OI, OSI, and mP aw over time were tested using Kruskal-Wallis analysis of variance (ANOVA) with post hoc comparisons, corrected for multiple testing. Analyses were conducted with Stata SE 14.2 (StataCorp, College Station, TX).
Multivariable logistic regression was performed to test for independent association between respiratory or oxygenation variables and mortality, after adjusting a priori for PRISM III, immunocompromised status, and OSI at iNO initiation. We have previously demonstrated that PRISM III and immunocompromised status are strongly associated with mortality in PARDS (25, 26) . OSI at iNO initiation was included to control for baseline PARDS severity and for univariate association with mortality (p = 0.039). Additional potential confounders were also considered, such as organ failures, vasopressor score, and fluid balance. These confounders were colinear with PRISM III and were not included. Additionally, no excluded variable improved model fit by likelihood ratio test. Model fit was assessed using Hosmer-Lemeshow statistics.
Competing risk regression was used to model the independent association of respiratory or oxygenation variables with duration of ventilation, using extubation as the primary outcome and death as the competing risk. Observations were censored at 28 days. Competing risk analysis using the Fine and Gray method (27) calculates a subdistribution hazard ratio (SHR) to estimate the risk of extubation, while accounting for the competing risk of death. The competing risk models were similarly adjusted for PRISM III, immunocompromised status, and OSI at iNO initiation. The proportional hazard assumption was assessed by testing for interaction with a time-dependent covariate.
RESULTS
One hundred sixty-one patients met inclusion criteria and were categorized as either iNO responders (n = 98) or nonresponders (n = 63). Based on the availability of arterial blood gases, OI was used to classify response in 135 children (84%), whereas OSI was used in 26 children (16%). Population characteristics, illness severity, and PARDS etiology were similar between iNO responders and nonresponders (Table 1) . Additionally, there was no difference in the incidence of pHTN markers in responders and nonresponders, such as elevated BNP (385 [138-1,664] vs 209 pg/mL; p = 0.295) and echocardiographic findings suggestive of pHTN (29% vs 29%; p = 0.999). Furthermore, although cardiac evaluation was only available in a limited number of patients within our cohort, patients with documented evidence of pHTN were not more likely to show response to iNO than the overall cohort: 60% of patients with pHTN were responders, and 60% of the entire cohort were responders.
Responders Table 1 At 6, 12, and 24 hours following iNO initiation, responders had significantly lower OI and OSI (Fig. 1, A and B) . There was no difference in mP aw between the two groups at any timepoint. However, iNO nonresponders had higher mP aw at 6 (p = 0.006) and 12 hours (p = 0.045) after iNO initiation relative to time 0 (Kruskal-Wallis ANOVA with post hoc comparisons corrected for multiple testing), whereas mP aw did not change at all over the first 24 hours in responders (Fig. 1C) .
iNO responders had significantly less exposure to highfrequency oscillatory ventilation (HFOV) (26% vs 41%; p = 0.039) and ECMO (5% vs 17%; p = 0.034). There was no difference in mortality between groups (21% vs 21%; p = 0.999), and response to iNO was not independently associated with PICU mortality in multivariable logistic regression ( Table 2 ) (Hosmer-Lemeshow χ 2 13.2; 8 degrees of freedom; p = 0.110). iNO responders had significantly lower hospital charges than nonresponders ($664,000 vs $1,088,000; p = 0.002).
Response to iNO was associated with significantly fewer ventilator days (10 [7-20] vs 16 ; p < 0.001). Competing risk regression analyses, accounting for competing risk of death, demonstrated that response to iNO was independently associated with earlier successful extubation (Table 3) (SHR = 2.11; 95% CI, 1.41-3.17; p < 0.001) after adjusting for PRISM III, immunocompromised status, and OSI at iNO initiation (Fig. 2) . Inclusion of echocardiographic evidence of pHTN in the model revealed an independent association with prolonged intubation (SHR = 0.57; 95% CI, 0.35-0.93; p = 0.025). However, the association between response to iNO and earlier extubation was not substantially modified (SHR, 2.46; 95% CI, 1.54-3.93; p < 0.001).
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DISCUSSION
Although there was no difference in mortality, iNO responsedefined by 20% improvement in OI or OSI at 6 hours-was associated with earlier successful separation from ventilator. Responders to iNO also had less frequent use of HFOV and ECMO, which may explain the shorter duration of ventilation and lower associated hospital costs.
This study suggests that there exists potential for a significant decrease in PARDS-associated morbidity with iNO therapy. Our mortality results agree with those of previous studies (4-10), though it has been argued that mortality in PARDS is usually secondary to nonpulmonary causes, making it unsurprising that improved oxygenation would have little effect on overall mortality (28) . However, previous studies did not evaluate for morbidity effects and selectively excluded certain populations of patients-such as those with immunocompromise, sepsis, and multisystem organ dysfunction-from analysis, which limits generalizability of the results to a significant portion of PICU patients (29, 30) . The largest study of iNO in PARDS to date propensity matched 521 PARDS patients who received iNO to those who did not and found no improvement in mortality or ventilator free days (11) . However, limitations in the database prevented matching patients by severity of hypoxemia or assessing change in oxygenation with therapy. Furthermore, the study excluded patients who received iNO for less than 1 day, although the effects of iNO may be seen within minutes or hours (10, 31) . Also excluded were a subset of patients unable to be propensity matched, such that ultimately only 40% of enrolled patients documented as having received iNO were included in the final data analysis. Finally, statistical techniques can only match on available variables, and the possibility of unmeasured confounding affecting the results remains. For all these reasons, the study results are difficult to interpret or apply to clinical practice. Our group's study adds data from a large PARDS cohort to the literature-the largest iNO exposed PARDS cohort with patient-level data-as well as a nuanced approach to evaluating the potential benefit of this salvage therapy in decreasing ventilator-associated morbidity. A previous attempt to separate adult ARDS patients by response to iNO in a randomized control trial only used improvement in Pao 2 to stratify patients, which can be confounded by changes in ventilator strategy (5) . Another randomized trial in adult ARDS noted differential iNO response between exposed patients but evaluated outcomes based on the combined sample of responders and nonresponders (10) . Additionally, the patients receiving iNO were exposed to different doses, as low as 1.25 ppm. The patients who received the lowest doses did not show an oxygenation response, but the outcomes of these patients were still pooled with those of the patients who received higher doses and did show oxygenation response. Another randomized trial of iNO in PARDS had a crossover design that made it difficult to evaluate survival and ventilation outcomes (16) . Finally, a pediatric randomized control trial by Bronicki et al (30) had a small number of iNO-exposed patients (24 patients), as compared to the 161 patients in the present study. Additionally, patients in the trial by Bronicki et al (30) were not stratified by iNO response, possibly secondary to the limited sample size. Without an adequate randomized control trial available in the literature, our finding of decreased duration of ventilation in a large iNO-responsive PARDS cohort is a significant addition to the PARDS literature.
Our results also show that, in addition to decreased duration of mechanical ventilation, iNO responders were less exposed to other sources of PICU morbidity that are frequently employed in the setting of refractory PARDS, such as HFOV and ECMO. These results are in keeping with those of some previous studies, such as a publication by Kinsella and Abman (32) demonstrating decreased need for ECMO in these patients and the previously mentioned trial by Bronicki et al (30) , which found decreased ECMO usage, as well as increased ventilator free days for the iNO arm. Lower usage of HFOV may be an additional mechanism for the observed decrease in duration of mechanical ventilation, as HFOV is associated with increased ventilator days (33) . The impact of decreasing ventilator and ECMO exposures may extend past hospital discharge. A recent paper on adult veno-veno ECMO outcomes found decreased quality of life even 6 months after ECMO exposure (34) . In addition to sparing responders from potential long-term effects of ECMO exposure, iNO itself may have lasting benefits. A 2012 study found that adult ARDS survivors who had been exposed to iNO had better pulmonary function test results 6 months after recovery than ARDS survivors without iNO exposure (35) . Furthermore, the data show that stratifying patients by response is cost effective, as iNO responders had lower hospital charges, potentially due to shorter ventilation, less HFOV, and less ECMO. Within our cohort, demographic variables were not predictive of iNO response. However, plasma angiopoietin 2 levels within 24 hours of iNO initiation were significantly higher in the patients who demonstrated iNO response. Angiopoietin 2 is a protein that destabilizes the endothelium (36) and has previously been shown to predict mortality in PARDS (12) . A possible mechanism for this finding is that more severe endothelial dysfunction, as indicated by elevated angiopoietin 2 levels, may lead to increased likelihood of sensitivity to the effects of iNO. Though our results need to be validated in a larger study, they suggest that angiopoietin 2 is a potential predictor of iNO response and can possibly be used to stratify patients in future iNO trials. Although angiopoietin 2 requires further study given the overlap between responders and nonresponders in the present sample, it is an attractive candidate for risk stratification in future iNO trials as it demonstrates both prognostic (higher risk of mortality) and predictive (higher chance of iNO response) enrichment.
This study is limited by its retrospective design and variability in physician practice among our group with regards to timing of iNO initiation and duration of iNO usage. This variability is secondary to lack of a standard institutional practice for iNO usage during the study time period. Our finding of continued use of iNO in nonresponders likely represents hesitance to discontinue therapies in patients with persistent hypoxia. This is an area in which quality improvement projects may be indicated. Our study is also limited by the extensive use of nonconventional ventilation, which precludes end-tidal Co 2 monitoring. Accordingly, we could not assess changes in alveolar dead space in response to iNO. A lack of serial echocardiography precludes longitudinal assessment of cardiac function after iNO initiation.
Future work in this cohort would include identification of predictors of iNO response, which could serve as basis for forming guidelines as to which patients are most likely to benefit from iNO therapy. However, it should be noted that neither demographic nor severity of illness variables predicted response to iNO in our cohort, and the finding that angiopoietin 2 discriminated iNO response is only preliminary. Continued enrollment will be necessary to power these additional analyses and potentially permit matching of responders and nonresponders for further analysis. Enrollment and generalizability of results may be augmented by development of a multicenter registry. Additionally, it is difficult to compare or propensity match iNO exposed and unexposed PARDS patients due to considerable differences in the characteristics of those populations.
As this is a retrospective study, we are unable to ascribe causality to the observed association of iNO response and shorter duration of mechanical ventilation. Thus, a randomized control trial will be necessary to discriminate if iNO response is causative of the observed decrease in morbidity or simply prognosticates which patients are likely to be liberated from mechanical ventilation faster, irrespective of whether the improved oxygenation is responsible for the shortened duration of ventilation. The fact that patients with documented pHTN were not more likely to be responders suggests that response to iNO is not simply a marker of reversible pHTN. Future studies may also consider usage of inhaled eprostanil to evaluate if cost differences persist between treatment responders and nonresponders when using this less-expensive pulmonary vasodilator.
CONCLUSIONS
In conclusion, these data suggest that a trial of iNO should be considered in patients with PARDS, given the positive association between iNO response and decreased ventilator days and hospital charges, as well as less exposure to ECMO and HFOV. The data also suggest that discontinuation of iNO therapy should be considered if there is no response and that there is room for improvement in development of iNO usage protocols. This therapy-response stratification approach is in keeping with the call for new ARDS treatment paradigms personalized to individual patient physiology (37) . Future studies on iNO and morbidity in PARDS should stratify patients based on oxygenation response to iNO, as it is associated with iNO response and poor outcomes.
